Please provide your email address to receive an email when new articles are posted on . The FDA issued draft guidance that would streamline testing of biosimilars. A separate plan would eliminate ...

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and ...

Employers are anticipating healthcare costs to increase substantially in 2026. A new Mercer study adds evidence to this projection, predicting that health benefit costs per employee will rise by an ...

As health plan sponsors prepare for 2026 open enrollment, they face familiar concerns of rising claims trends and labor costs, while also confronting new ERISA litigation risks tied to pharmacy ...